Developing new therapies

In collaboration with other laboratories at Dana-Farber Cancer Institute/Harvard and partners from the pharmaceutical industry, the Jänne Lab screens newly developed agents and large-scale compound libraries against patient-derived cell lines and patient-derived xenograft mouse models with unique genetic signatures. Our goal is to:

  • Identify and further develop therapies against oncogenic and/or resistance-imparting mutations with no available or no satisfactory treatment options  
  • Design therapeutic approaches to address biological processes that can be exploited to target cancer cells more effectively and permanently
  • Translate laboratory findings to directly benefit patients with no clear alternative treatment option

Image showing translational diagram

[click image to enlarge]